PMID- 27394687
OWN - NLM
STAT- MEDLINE
DCOM- 20180308
LR  - 20180830
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 649
DP  - 2017 May 10
TI  - MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative 
      therapeutics".
PG  - 176-180
LID - S0304-3940(16)30490-6 [pii]
LID - 10.1016/j.neulet.2016.07.004 [doi]
AB  - There is a range of therapies to treat Post Traumatic Stress Disorder (PTSD) but 
      treatment resistance remains high, with many sufferers experiencing the chronic 
      condition. Engagement in trauma-focused psychotherapy is difficult for some 
      patients with PTSD, especially those with extreme affect dysregulation associated 
      with recall of traumatic memories. In recent years there have been a number of 
      neuroscientific and clinical studies examining the potential role for adjunctive 
      drug-assisted psychotherapy using 3,4,-methylenedioxmethamphetamine (MDMA) as a 
      treatment for PTSD. re-visiting of a novel approach to trauma-focused 
      psychotherapy with Used just two or three times, under careful medical 
      supervision and specialised psychotherapy support MDMA appears to facilitate the 
      recall of traumatic memories without the user feeling overwhelmed by the negative 
      affect that usually accompanies such memories. This therapeutic approach began in 
      the 1980s and was subsequently shelved in the midst of public health concerns 
      surrounding the recreational use of the drug ecstasy. When pharmaceutical grade 
      MDMA is used in a clinical setting it does not share the same risk profiles as 
      ecstasy. Recent phase one neurophysiological studies and phase two clinical 
      studies are showing promise as a potential new approach to managing 
      treatment-resistant PTSD.
CI  - Crown Copyright (c) 2016. Published by Elsevier B.V. All rights reserved.
FAU - Sessa, Ben
AU  - Sessa B
AD  - Consultant Addictions Psychiatrist, Imperial College London, United Kingdom. 
      Electronic address: b.sessa@imperial.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160706
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Memory/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/adverse effects/*therapeutic use
MH  - Stress Disorders, Post-Traumatic/*drug therapy/physiopathology/psychology
OTO - NOTNLM
OT  - MDMA
OT  - PTSD
EDAT- 2016/07/11 06:00
MHDA- 2018/03/09 06:00
CRDT- 2016/07/11 06:00
PHST- 2016/06/01 00:00 [received]
PHST- 2016/07/02 00:00 [revised]
PHST- 2016/07/05 00:00 [accepted]
PHST- 2016/07/11 06:00 [pubmed]
PHST- 2018/03/09 06:00 [medline]
PHST- 2016/07/11 06:00 [entrez]
AID - S0304-3940(16)30490-6 [pii]
AID - 10.1016/j.neulet.2016.07.004 [doi]
PST - ppublish
SO  - Neurosci Lett. 2017 May 10;649:176-180. doi: 10.1016/j.neulet.2016.07.004. Epub 
      2016 Jul 6.